Overview

Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

This study introduces a new optimization immunosuppressive regimen associating tacrolimus at a reduced dose and enteric-coated mycophenolate sodium at an increased dose in order to slow down renal function worsening and to prevent the progression of chronic allograft nephropathy, while maintaining the same efficacy, in maintenance renal transplant recipients.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Tacrolimus